Abstract
Replacing the naphthalene C-unit of the anti-tuberculosis drug bedaquiline with a range of bicyclic heterocycles of widely differing lipophilicity gave analogs with a 4.5-fold range in clogP values. The biological results for these compounds indicate on average a lower clogP limit of about 5.0 in this series for retention of potent inhibitory activity (MIC90s) against M.tb in culture. Some of the compounds also showed a significant reduction in inhibition of hERG channel potassium current compared with bedaquiline, but there was no common structural feature that distinguished these.
Keywords:
Bedaquiline; Bedaquiline analogs; Drug development; Tuberculosis.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antitubercular Agents / chemical synthesis
-
Antitubercular Agents / chemistry
-
Antitubercular Agents / pharmacology*
-
Bridged Bicyclo Compounds, Heterocyclic / chemical synthesis
-
Bridged Bicyclo Compounds, Heterocyclic / chemistry
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Cell Line, Tumor
-
Diarylquinolines / chemistry
-
Diarylquinolines / pharmacology*
-
Dose-Response Relationship, Drug
-
Humans
-
Microbial Sensitivity Tests
-
Molecular Structure
-
Mycobacterium tuberculosis / drug effects*
-
Naphthalenes / chemistry
-
Naphthalenes / pharmacology*
-
Structure-Activity Relationship
Substances
-
Antitubercular Agents
-
Bridged Bicyclo Compounds, Heterocyclic
-
Diarylquinolines
-
Naphthalenes
-
naphthalene
-
bedaquiline